Novel perfluorocarbon-based oxygenation therapy alleviates Post-SAH hypoxic brain injury by inhibiting HIF-1α
Novel perfluorocarbon-based oxygenation therapy alleviates Post-SAH hypoxic brain injury by inhibiting HIF-1α
复制标题
新型基于全氟化碳的氧疗通过抑制缺氧诱导因子-1α（HIF-1α）来减轻蛛网膜下腔出血（SAH）后的缺氧性脑损伤。
DOI：
10.1016/j.freeradbiomed.2024.02.002
复制
发表时间：
2024-02-21
影响因子：
7.4
通讯作者：
Zhuang，Zong
中科院分区：
文献类型：
--
作者：
Peng，Zheng;Ye，Qing-Song;Zhuang，Zong
In comparison to other stroke types, subarachnoid hemorrhage (SAH) is characterized by an early age of onset and often results in poor prognosis. The inadequate blood flow at the site of the lesion leads to localized oxygen deprivation, increased level of hypoxia-inducible factor-1α (HIF-1α), and triggers inflammatory responses and oxidative stress, ultimately causing hypoxic brain damage. Despite the potential benefits of oxygen (O2) administration, there is currently a lack of efficient focal site O2delivery following SAH. Conventional clinical O2supply methods, such as transnasal oxygenation and hyperbaric oxygen therapy, do not show the ideal therapeutic effect in severe SAH patients. The perfluorocarbon oxygen carrier (PFOC) demonstrates efficacy in transporting O2and responding to elevated levels of CO2at the lesion site. Through cellular experiments, we determined that PFOC oxygenation serves as an effective therapeutic approach in inhibiting hypoxia. Furthermore, our animal experiments showed that PFOC oxygenation outperforms O2breathing, leading to microglia phenotypic switching and the suppression of inflammatory response via the inhibition of HIF-1α. Therefore, as a new type of O2therapy after SAH, PFOC oxygenation can effectively reduce hypoxic brain injury and improve neurological function.
